Patheon Expands PDS Capacity In Canada

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has opened a new Pharmaceutical Development Services (PDS) suite at the Whitby Development Centre in Canada. The suite includes a designated area for the small-scale development and manufacturing of solid dosage forms for customers' early clinical study needs.

The 2500 sq ft suite is designed to give rapid response, and the facility is GMP-compliant for manufacturing products for Phase I & II clinical studies. By providing clinical trial materials for First Time in Human (Phase I) studies, the suite will contribute to Patheon's Quick To Clinic™ offering. The new facility will also add early-phase pharmaceutical development and manufacturing capacity, with a manufacturing scale of 1kg to 10kg.

The suite has multiple labs with the capability for small-scale dosage form development, as well as the manufacture of powder-in-bottle, tablets (immediate and modified release), capsules, oral liquids, and nasal sprays.

Colin Minchom, PhD, Vice President, Pharmaceutical Development Services, Canada, stated, "We're very excited about the rapid response capabilities of the new Whitby suite. This new facility will significantly strengthen Patheon's competitiveness in the pharmaceutical and biotechnology early development arena."

Terry Novak, President, North America and Chief Marketing Officer, added, "Patheon is committed to investing in its development services business and with this new capacity in Whitby; we can now offer rapid early phase development to our North American customers."

About Patheon
Patheon Inc. (www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated network strives to ensure that customer products can be launched with confidence globally.

SOURCE: Patheon Inc.